Conventional medical therapies for glycemic control demonstrate limited efficacy in NICTH: intravenous glucose provides only transient relief, and glucocorticoids, glucagon, GH, or somatostatin analogs often fail to suppress IGF-2-mediated hypoglycemia (18–25). This evidence concerns the gene GH1 and Hypoglycemia.